- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Kallikrein 13 Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP6332b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Kallikrein 13 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | Q9UKR3 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 30570 Da |
Kallikrein 13 Antibody (C-term) - Additional info | |
| Gene ID 26085 | |
| Other Names KLK13; KLKL4; Kallikrein-13; Kallikrein-like protein 4 | |
| Target/Specificity This Kallikrein 13 Antibody antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 248~277 amino acids from the C-terminal region of human KLK13. | |
| Dilution WB~~1:50~100WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Kallikrein 13 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
Kallikrein 13 Antibody (C-term) - Protein Information | |
| Name KLK13 | |
| Synonyms KLKL4 | |
| Cellular Location Secreted (Probable). | |
| Tissue Location Expressed in prostate, breast, testis and salivary gland | |
Kallikrein 13 Antibody (C-term) - Related products
AP6332a: Kallikrein 13 Antibody (Center)
AP6332b: Kallikrein 13 Antibody (C-term)
RI12925: KLK13 predesign siRNA
DC08711: Human KLK13 cDNA Clone
Kallikrein 13 Antibody (C-term) - Application data
-
Western blot analysis of Kallikrein 13 (KLK13) antibody (C-term) (Cat.# AP6332b) in Jurkat cell line lysates (35ug/lane). Kallikrein 13(arrow) was detected using the purified Pab.
Kallikrein 13 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Expression of KLK13 is regulated by steroid hormones and may be useful as a marker for breast cancer.
REFERENCES
Kapadia, C., et al., Biochem. Biophys. Res. Commun. 323(3):1084-1090 (2004). Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003). Chang, A., et al., Br. J. Cancer 86(9):1457-1464 (2002). Chang, A., et al., Anticancer Res. 21(5):3147-3152 (2001). Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).
